메뉴 건너뛰기




Volumn 1, Issue 5, 1998, Pages 495-501

Research and development of antibacterial agents

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIA (MICROORGANISMS);

EID: 0032173613     PISSN: 13695274     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1369-5274(98)80080-5     Document Type: Article
Times cited : (45)

References (45)
  • 1
    • 0028034160 scopus 로고
    • How the pharmaceutical industry brings an antibiotic drug to market in the United States
    • Billstein SA: How the pharmaceutical industry brings an antibiotic drug to market in the United States. Antimicrob Agents Chemother 1994, 38:2679-2682.
    • (1994) Antimicrob Agents Chemother , vol.38 , pp. 2679-2682
    • Billstein, S.A.1
  • 2
    • 0030921538 scopus 로고    scopus 로고
    • Emergent antibiotic resistance: Health risks and economic impact
    • Cassell GH: Emergent antibiotic resistance: health risks and economic impact. FEMS Immunol Med Microbiol 1997, 18:271-274. This paper describes current problems of bacterial drug resistance and considers consequent socio-economic issues.
    • (1997) FEMS Immunol Med Microbiol , vol.18 , pp. 271-274
    • Cassell, G.H.1
  • 3
    • 0039229975 scopus 로고    scopus 로고
    • Evolution of antibiotic resistance
    • Baquero F, Blazquez J: Evolution of antibiotic resistance. Trends Ecol Evol 1997, 12:482-487. This paper summarises the principal mechanisms of resistance to antibacterial agents and describes the genetic basis of acquired drug resistance.
    • (1997) Trends Ecol Evol , vol.12 , pp. 482-487
    • Baquero, F.1    Blazquez, J.2
  • 4
    • 0031037207 scopus 로고    scopus 로고
    • The search for antimicrobial agents effective against bacteria resistant to multiple antibiotics
    • Chopra I, Hodgson J, Metcalf B, Poste G: The search for antimicrobial agents effective against bacteria resistant to multiple antibiotics. Antimicrob Agents Chemother 1997, 41:497-503. This paper discusses various strategies for drug discovery and describes the molecular techniques that will permit the targeting of products associated with infection.
    • (1997) Antimicrob Agents Chemother , vol.41 , pp. 497-503
    • Chopra, I.1    Hodgson, J.2    Metcalf, B.3    Poste, G.4
  • 5
    • 0030774640 scopus 로고    scopus 로고
    • New strategies for antibacterial drug design
    • Knowles DJC: New strategies for antibacterial drug design. Trends Microbiol 1997, 5:379-383. This paper provides a historical perspective on drug discovery strategies and also describes the new molecular techniques thai will permit the targeting of bacterial infection processes.
    • (1997) Trends Microbiol , vol.5 , pp. 379-383
    • Knowles, D.J.C.1
  • 7
    • 0029794181 scopus 로고    scopus 로고
    • Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae
    • Pan X-S, Ambler J, Mehtar S, Fisher ML: Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrob Agents Chemother 1996, 40:2321-2326.
    • (1996) Antimicrob Agents Chemother , vol.40 , pp. 2321-2326
    • Pan, X.-S.1    Ambler, J.2    Mehtar, S.3    Fisher, M.L.4
  • 8
    • 0030757351 scopus 로고    scopus 로고
    • The chemistry and biological profile of trovafloxacin
    • Brighty KE, Gootz TD: The chemistry and biological profile of trovafloxacin. J Antimicrob Chemother 1997, 39(Suppl B):1-14. In addition to describing trovafloxacin, this paper provides a very useful summary of structure/function relationships for other new fluoroquinolones.
    • (1997) J Antimicrob Chemother , vol.39 , Issue.SUPPL. B , pp. 1-14
    • Brighty, K.E.1    Gootz, T.D.2
  • 9
    • 0031306984 scopus 로고    scopus 로고
    • Grepafloxacin - Focus on respiratory infections
    • Geddes AM: Grepafloxacin - focus on respiratory infections. J Antimicrob Chemother 1997, 40(suppl A):1-4.
    • (1997) J Antimicrob Chemother , vol.40 , Issue.SUPPL. A , pp. 1-4
    • Geddes, A.M.1
  • 10
    • 0030831857 scopus 로고    scopus 로고
    • Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin
    • Bauernfeind A: Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. J Antimicrob Chemother 1997, 40:639-651.
    • (1997) J Antimicrob Chemother , vol.40 , pp. 639-651
    • Bauernfeind, A.1
  • 12
    • 0031409343 scopus 로고    scopus 로고
    • Molecular action of anti-mycobacterial agents
    • Chopra I, Brennan P: Molecular action of anti-mycobacterial agents. Tubercle Lung Dis 1998, 78:89-98. This paper provides a summary of the mechanisms of action of established antimycobacterial drugs and describes new agents in development.
    • (1998) Tubercle Lung Dis , vol.78 , pp. 89-98
    • Chopra, I.1    Brennan, P.2
  • 13
    • 0031931286 scopus 로고    scopus 로고
    • Antimicrobial activities of benzoxazinorifamycin KRM-1648, clarithromycin and levofloxacin against intracellular Mycobacterium avium complex phagocytosed by murine peritoneal macrophages
    • Sato K, Akaki T, Tomioka H: Antimicrobial activities of benzoxazinorifamycin KRM-1648, clarithromycin and levofloxacin against intracellular Mycobacterium avium complex phagocytosed by murine peritoneal macrophages. J Antimicrob Chemother 1998, 41:77-83.
    • (1998) J Antimicrob Chemother , vol.41 , pp. 77-83
    • Sato, K.1    Akaki, T.2    Tomioka, H.3
  • 15
    • 0024435166 scopus 로고
    • New directions for macrolide antibiotics: Structural modifications and in vitro activity
    • Kirst HA, Sides GD: New directions for macrolide antibiotics: structural modifications and in vitro activity. Antimicrob Agents Chemother 1989, 33:1413-1418.
    • (1989) Antimicrob Agents Chemother , vol.33 , pp. 1413-1418
    • Kirst, H.A.1    Sides, G.D.2
  • 16
    • 0024442066 scopus 로고
    • New directions for macrolide antibiotics: Pharmacokinetics and clinical efficacy
    • Kirst HA, Sides GD: New directions for macrolide antibiotics: pharmacokinetics and clinical efficacy. Antimicrob Agents Chemother 1989, 33:1419-1422.
    • (1989) Antimicrob Agents Chemother , vol.33 , pp. 1419-1422
    • Kirst, H.A.1    Sides, G.D.2
  • 19
    • 0343742636 scopus 로고    scopus 로고
    • In vitro activity of RU64004, a new ketolide antibiotic, against Grampositive bacteria
    • Schulin T, Wennersten CB, Moellering RC, Eliopoulos GM: In vitro activity of RU64004, a new ketolide antibiotic, against Grampositive bacteria. Antimicrob Agents Chemother 1997, 41:1196-1202. This is the first paper to present comprehensive data on the antibacterial activity of the development ketolide RU64004 against clinical isolates.
    • (1997) Antimicrob Agents Chemother , vol.41 , pp. 1196-1202
    • Schulin, T.1    Wennersten, C.B.2    Moellering, R.C.3    Eliopoulos, G.M.4
  • 20
    • 0031040129 scopus 로고    scopus 로고
    • Oxazolidinone antibacterial agents; development of the clinical candidates eperezolid and linezolid
    • Zurenko GW, Ford CW, Hutchinson DK, Brickner SJ, Barbachyn MR: Oxazolidinone antibacterial agents; development of the clinical candidates eperezolid and linezolid. Exp Opin Invest Drugs 1997. 6:151-158. This paper discusses the mechanism of action of the oxazolidinones, their synthesis, structure-activity relationships, antibacterial spectrum and data from Phase I clinical trials.
    • (1997) Exp Opin Invest Drugs , vol.6 , pp. 151-158
    • Zurenko, G.W.1    Ford, C.W.2    Hutchinson, D.K.3    Brickner, S.J.4    Barbachyn, M.R.5
  • 22
    • 0030793842 scopus 로고    scopus 로고
    • Mechanism of action of oxazolidinones: Effects of linezolid and eperezolid on translation reactions
    • Shinabarger DL, Marotti KR, Murray RW, Lin AH, Melchior EP, Swaney SM, Dunyak DS, Demyan WF, Buysse JM: Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions. Antimicrob Agents Chemother 1997, 41:2132-2136. This paper presents data that the mechanism of action of the oxazolidinones involves prevention of mRNA binding to the ribosome at the initiation phase of translation.
    • (1997) Antimicrob Agents Chemother , vol.41 , pp. 2132-2136
    • Shinabarger, D.L.1    Marotti, K.R.2    Murray, R.W.3    Lin, A.H.4    Melchior, E.P.5    Swaney, S.M.6    Dunyak, D.S.7    Demyan, W.F.8    Buysse, J.M.9
  • 23
    • 0031956779 scopus 로고    scopus 로고
    • Ribosomes from an oxazolidinone-resistant mutant confer resistance to eperezolid in a Staphylococcus aureus cell-free transcription-translation assay
    • Murray RW, Schaadt RD, Zurenko GE, Marotti KR: Ribosomes from an oxazolidinone-resistant mutant confer resistance to eperezolid in a Staphylococcus aureus cell-free transcription-translation assay. Antimicrob Agents Chemother 1998, 42:947-950. This paper describes the isolation of an eperezolid-resistant mutant of S. aureus by prolonged drug exposure and its use to confirm that resistance (and by inference the drug target) is expressed at the level of the ribosome.
    • (1998) Antimicrob Agents Chemother , vol.42 , pp. 947-950
    • Murray, R.W.1    Schaadt, R.D.2    Zurenko, G.E.3    Marotti, K.R.4
  • 26
    • 0030660723 scopus 로고    scopus 로고
    • The renewed challenge of antibacterial chemotherapy
    • Niccolai D, Tarsi L, Thomas RJ: The renewed challenge of antibacterial chemotherapy. Chem Commun 1997:2333-2342. This paper reviews most of the antibacterial agents currently in development, with an emphasis on their chemical synthesis.
    • (1997) Chem Commun , pp. 2333-2342
    • Niccolai, D.1    Tarsi, L.2    Thomas, R.J.3
  • 27
    • 0030983411 scopus 로고    scopus 로고
    • Inhibition of protein synthesis by streptogramins and related antibiotics
    • Cocito C, Di Giambattista M, Nyssen E, Vannuffel P: Inhibition of protein synthesis by streptogramins and related antibiotics. J Antimicrob Chemother 1997, 39(suppl A):7-13.
    • (1997) J Antimicrob Chemother , vol.39 , Issue.SUPPL. A , pp. 7-13
    • Cocito, C.1    Di Giambattista, M.2    Nyssen, E.3    Vannuffel, P.4
  • 29
    • 0031983595 scopus 로고    scopus 로고
    • In vitro activity of sanfetrinem and affinity for the penicillin-binding proteins of Streptococcus pneumoniae
    • Sifaoui F, Varon E, Kitzis M-D, Gutmann L: In vitro activity of sanfetrinem and affinity for the penicillin-binding proteins of Streptococcus pneumoniae. Antimicrob Agents Chemother 1998, 42:173-175. This paper provides evidence that the tribactam sanfetrinem promotes killing of penicillin-resistant pneumococci by interaction with penicillin-binding proteins 1a and 2b.
    • (1998) Antimicrob Agents Chemother , vol.42 , pp. 173-175
    • Sifaoui, F.1    Varon, E.2    Kitzis, M.-D.3    Gutmann, L.4
  • 30
    • 0031908863 scopus 로고    scopus 로고
    • Novel C-2 substituted carbapenem derivatives. Part IV. Synthesis and biological activity of five membered heteroaromatic derivatives
    • Branch CL, Burton G, Clarke GJ, Coulton S, Douglas JD, Eglington AJ, Guest AW, Hinks JD, Hird NW, Holland RK et al.: Novel C-2 substituted carbapenem derivatives. Part IV. Synthesis and biological activity of five membered heteroaromatic derivatives. J Antibiotics 1998, 51:21 0-220. This paper describes the synthesis and properties of a range of novel carbapenems which are particularly active against community-acquired respiratory pathogens, including penicillin-resistant strains that do not produce β-lactamase.
    • (1998) J Antibiotics , vol.51 , pp. 210-220
    • Branch, C.L.1    Burton, G.2    Clarke, G.J.3    Coulton, S.4    Douglas, J.D.5    Eglington, A.J.6    Guest, A.W.7    Hinks, J.D.8    Hird, N.W.9    Holland, R.K.10
  • 31
    • 0023691243 scopus 로고
    • Iron-regulated outer membrane proteins of Escherichia coli K-12 and mechanism of action of catechol-substituted cephalosporins
    • Curtis NAC, Eisensladt RL, East SJ, Cornford RJ, Walker LA, White AJ: Iron-regulated outer membrane proteins of Escherichia coli K-12 and mechanism of action of catechol-substituted cephalosporins. Antimicrob Agents Chemother 1988, 32:1879-1886.
    • (1988) Antimicrob Agents Chemother , vol.32 , pp. 1879-1886
    • Nac, C.1    Eisensladt, R.L.2    East, S.J.3    Cornford, R.J.4    Walker, L.A.5    White, A.J.6
  • 34
    • 0030902573 scopus 로고    scopus 로고
    • Antibacterial activity of BMS-180680, a new catechol-containing monobactam
    • Fung-Tomc J, Bush K, Minassian B, Kolek B, Flamm R, Gradelski E, Bonner D: Antibacterial activity of BMS-180680, a new catechol-containing monobactam. Antimicrob Agents Chemother 1997, 41:1010-1016. This paper presents evidence that the investigational compound BMS-180680 utilises TonB-dependent transport systems for enhanced uptake across the bacterial outer membrane, which results in potent in vitro activity against several organisms, including Pseudomonas aeruginosa.
    • (1997) Antimicrob Agents Chemother , vol.41 , pp. 1010-1016
    • Fung-Tomc, J.1    Bush, K.2    Minassian, B.3    Kolek, B.4    Flamm, R.5    Gradelski, E.6    Bonner, D.7
  • 35
    • 0030751187 scopus 로고    scopus 로고
    • Beyond vancomycin: New therapies to meet the challenge of glycopeptide resistance
    • Nicas TI, Zeckel ML, Braun DK: Beyond vancomycin: new therapies to meet the challenge of glycopeptide resistance. Trends Microbiol 1997, 5:240-249. This paper considers the current problems of resistance in Gram-positive pathogens and discusses the discovery and development of new glycopeptides, streptogramins and oxazolidinones.
    • (1997) Trends Microbiol , vol.5 , pp. 240-249
    • Nicas, T.I.1    Zeckel, M.L.2    Braun, D.K.3
  • 36
    • 0027266017 scopus 로고
    • Genetics and mechanisms of glycopeptide resistance in enterococci
    • Arthur M, Courvalin P: Genetics and mechanisms of glycopeptide resistance in enterococci, Antimicrob Agents Chemother 1993, 37:1563-1571.
    • (1993) Antimicrob Agents Chemother , vol.37 , pp. 1563-1571
    • Arthur, M.1    Courvalin, P.2
  • 37
    • 0031038392 scopus 로고    scopus 로고
    • Molecular interactions of a semisynthetic glycopeptide antibiotic with D-alanyl-D-alanine and D-alanyl-D-lactate residues
    • Allen NE, Le Tourney DL, Hobbs JN: Molecular interactions of a semisynthetic glycopeptide antibiotic with D-alanyl-D-alanine and D-alanyl-D-lactate residues. Antimicrob Agents Chemother 1997, 41:66-71 This paper presents data on the binding affinities of LY191145 and vancomycin for residues in peptidoglycan, and the dimerisation constants of these glycopeptides.
    • (1997) Antimicrob Agents Chemother , vol.41 , pp. 66-71
    • Allen, N.E.1    Le Tourney, D.L.2    Hobbs, J.N.3
  • 38
    • 0030841073 scopus 로고    scopus 로고
    • Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility
    • Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC: Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997, 40:135-136.
    • (1997) J Antimicrob Chemother , vol.40 , pp. 135-136
    • Hiramatsu, K.1    Hanaki, H.2    Ino, T.3    Yabuta, K.4    Oguri, T.5    Tenover, F.C.6
  • 40
    • 0031975655 scopus 로고    scopus 로고
    • The therapeutic potential of cationic peptides
    • Hancock REW: The therapeutic potential of cationic peptides. Exp Opin Invest Drugs 1998, 7:167-174. This review describes the properties of various cationic peptides with an emphasis on their development as therapeutic agents.
    • (1998) Exp Opin Invest Drugs , vol.7 , pp. 167-174
    • Rew, H.1
  • 41
    • 0032007854 scopus 로고    scopus 로고
    • Cationic peptides: A new source of antibiotics
    • Hancock REW, Lehrer R: Cationic peptides: a new source of antibiotics. Trends Biotechnol 1998, 16:82-88. This review describes the properties and potential applications of cationic peptides and provides more detailed descriptions of their structures and mode of action than [40"].
    • (1998) Trends Biotechnol , vol.16 , pp. 82-88
    • Rew, H.1    Lehrer, R.2
  • 42
    • 23444440823 scopus 로고
    • Inactivation of antibiotics and the dissemination of resistance genes
    • Davies J: Inactivation of antibiotics and the dissemination of resistance genes. Science 1994, 264:375-382.
    • (1994) Science , vol.264 , pp. 375-382
    • Davies, J.1
  • 43
    • 0031007336 scopus 로고    scopus 로고
    • Conditionally lethal Escherichia coli mutants contain point defects that map to regions conserved among murein and folyl poly-γ-glutamate ligases: Identification of a ligase superfamily
    • Eveland SS, Pompliano DL, Anderson MS: Conditionally lethal Escherichia coli mutants contain point defects that map to regions conserved among murein and folyl poly-γ-glutamate ligases: identification of a ligase superfamily. Biochemistry 1997, 36:6223-6229.
    • (1997) Biochemistry , vol.36 , pp. 6223-6229
    • Eveland, S.S.1    Pompliano, D.L.2    Anderson, M.S.3
  • 44
    • 0030763951 scopus 로고    scopus 로고
    • Novel targets for antibiotics - An update
    • Isaacson RE: Novel targets for antibiotics - an update. Exp Opin Invest Drugs 1997, 6:1009-1017. This paper considers the opportunities for inhibiting bacterial Infection processes with drugs and the benefits this approach would have for minimising selection of drug-resistant variants.
    • (1997) Exp Opin Invest Drugs , vol.6 , pp. 1009-1017
    • Isaacson, R.E.1
  • 45
    • 0030970590 scopus 로고    scopus 로고
    • Inhibition of virulence factors in bacteria
    • Goldschmidt RM, Macielag MJ, Hlasta DJ, Barrett JF: Inhibition of virulence factors in bacteria. Curr Pharm Des 1997, 3:125-142. This paper provides a comprehensive review of new opportunities for inhibition of bacterial infection processes and describes some investigational compounds that appear to either affect infection processes directly, or prevent the organisms from adapting to an in vivo environment.
    • (1997) Curr Pharm des , vol.3 , pp. 125-142
    • Goldschmidt, R.M.1    Macielag, M.J.2    Hlasta, D.J.3    Barrett, J.F.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.